Cardiopulmonary function during exercise in heart failure with reduced ejection fraction following baroreflex activation therapy

Pia I. Nottebohm, Daniel Dumitrescu, Stefanie Hamacher, Christopher Hohmann, Navid Madershahian, Stephan Baldus, Hannes Reuter and Marcel Halbach

Abstract

Purpose: Baroreflex activation therapy has favorable effects in heart failure patients. We report the results of a single-center study of baroreflex activation therapy in heart failure with reduced ejection fraction including cardiopulmonary exercise testing for the first time to show the effect on exercise capacity.

Methods: A total of 17 patients were treated with baroreflex activation therapy. Eligibility criteria were the New York Heart Association class ≥III and ejection fraction ≤35% on guideline-directed medical and device therapy. The New York Heart Association class, quality of life, and 6-min hall walk distance were assessed in all patients. Twelve patients underwent cardiopulmonary exercise testing before and 8.9 ± 6.4 months after initiation of baroreflex activation therapy.

Results: The New York Heart Association class and 6-min hall walk distance improved after baroreflex activation therapy, while quality of life remained stable. Weight-adapted peak oxygen uptake increased significantly from 10.1 (8.2–12.9) ml/min/kg to 12.1 (10.4–14.6) ml/min/kg (p = 0.041). Maximal heart rate was stable. Maximal oxygen pulse increased from 9.7 (5.5–11.3) to 9.9 (7.1–12.1) ml/heartbeat (p = 0.047) in 10 patients with low maximal oxygen pulse at baseline (<16.5 ml/heartbeat). There was no significant change in maximal oxygen pulse in the whole cohort. Ventilatory efficiency remained stable.

Conclusion: Weight-adapted peak oxygen uptake improved after baroreflex activation therapy, pointing to an enhanced exercise capacity. Ventilatory efficiency and heart rate did not change, while oxygen pulse increased in patients with low oxygen pulse at baseline, indicating an improvement in circulatory efficiency, that is, a beneficial effect on stroke volume and peripheral oxygen extraction.

Keywords: baroreflex activation therapy, carotid sinus stimulation, CPET, heart failure

Introduction

The imbalance of the autonomic nervous system – that is, an activation of the sympathetic and inhibition of the parasympathetic component – promotes the development and progression of heart failure with reduced ejection fraction (HFrEF). The high sympathetic tone leads to further sympathetic activation, so patients with chronic HFrEF are trapped in a vicious circle. β-blockers and inhibitors of the renin–angiotensin–aldosterone system interrupt this vicious circle, and thereby have beneficial effects on morbidity and mortality of patients with HFrEF.

Baroreflex activation therapy (BAT) – that is, electrical stimulation of baroreceptors by a subclavicular pulse generator connected to a carotid
sinus lead – causes a central inhibition of sympathetic tone, as evidenced by a reduction of muscle sympathetic nerve activity (MSNA) in patients with HFrEF.\(^6\) Thereby, BAT may interrupt the vicious circle one step earlier than drugs do.\(^3\) The first randomized, controlled clinical trial of BAT involving 146 patients with HFrEF has shown an acceptable safety and a statistically significant enhancement in the New York Heart Association (NYHA) class, quality-of-life score, 6-min hall walk distance (6MHW), and N-terminal pro-brain natriuretic peptide (NTproBNP). Left ventricular ejection fraction (LVEF) was numerically enhanced under BAT. Preliminary results of a larger, still ongoing trial confirmed the initial findings and pointed toward a reduction of cardiovascular events under BAT.\(^7\)

These trials did not include any data on enhanced testing of cardiopulmonary function, which may add substantial information on the mode of action of BAT and provide further objective evidence of its efficacy. We hypothesized that BAT would improve peak oxygen uptake, which is a key parameter of cardiopulmonary function. Here, we report the results of a single-center, open-label study of BAT in HFrEF, which includes cardiopulmonary function testing for the first time.

**Methods**

*Eligibility criteria, implantation procedure, and therapy*

Initial eligibility criteria for BAT were NYHA class ≥III and ejection fraction ≤35% on stable guideline-directed medical and device therapy. Reversible causes of heart failure like untreated valvular heart disease or acute myocarditis were exclusion criteria.

The Barostim neo™ system (CVRx Inc., Minneapolis, MN, USA) and the implantation procedure have been described in detail before.\(^2,8\) Briefly, the basic principle of BAT is to stimulate baroreceptors by a pulse generator connected to a small unipolar electrode, which is sutured onto the carotid sinus wall. The lead is tunneled subcutaneously to the pulse generator implanted in the subclavicular region, similar to a pacemaker. BAT was activated within 2 weeks after implantation. Electrical stimulation intensity was titrated over a series of follow-up visits up to the threshold of side effects. The patients’ maximum tolerable dose differed.

**Endpoints and examinations**

A total of 17 patients with HFrEF were treated with BAT at our center. Patients were enrolled in a multicenter registry (ClinicalTrials.Gov Identifier: NCT02880618) or a multicenter randomized trial [Health Outcomes Prospective Evaluation for Heart Failure (HOPE-4-HF), ClinicalTrials.Gov Identifier: NCT01720160]. Endpoints collected in the registry and randomized trial were NYHA class, 6MHW, LVEF, Minnesota Living with Heart Failure Questionnaire (MLHFQ) score and serum biomarkers as NTproBNP, serum creatinine, and estimated glomerular filtration rate (eGFR) at 6- and 12-month follow-up. Although patients were enrolled in these multicenter studies, all parameters included in the present analysis were not derived from the study databases, but from a retrospective evaluation of our local clinical database. The sponsor of the above-mentioned multicenter studies approved the publication of our local data.

As part of the routine heart failure investigations at our institution, which was not included in the registry or randomized trial, 12 patients at our center underwent cardiopulmonary exercise testing (CPET) before and after initiation of BAT. Moreover, metanephrines and normetanephrines were analyzed. As these parameters were not part of the registry or the randomized trial, the time-points of baseline and follow-up examinations were more variable, and data were not available for all 17 patients at all time-points.

The first activation took place on 2 September 2011. The first baseline value was measured on 10 August 2011, and the final follow-up was on 6 May 2017. The protocols of the prospective registry and randomized trial conformed to the Declaration of Helsinki and were approved by the local ethics committee and regulatory authorities. Additional local investigations were also approved by the local ethics committee (no. 15-344). Patients provided written informed consent for all investigations before enrollment.

**CPET protocol**

Relevant parameters of exercise capacity as well as circulatory and ventilatory efficiency were
analyzed by CPET, performed with incremental workload (10–20 watts/minute) up to maximal individual tolerance. Key parameters included peak oxygen uptake (peak VO\textsubscript{2}), maximal oxygen pulse, defined as the amount of oxygen uptake per heartbeat (peak VO\textsubscript{2}/peak heart rate), ventilatory efficiency, expressed as the relationship between minute ventilation and carbon dioxide output (VE/VCO\textsubscript{2}-slope), and end-tidal CO\textsubscript{2} partial pressure (PETCO\textsubscript{2}). General reproducibility of peak VO\textsubscript{2} measured in our laboratory was confirmed by repeated CPET in six patients with HFrEF not treated by BAT. Peak VO\textsubscript{2} in these six control patients was 14.7 ± 4.2 ml/min/kg at the first test and 14.5 ± 3.0 ml/min/kg at the second test (p = 0.74, interval between tests 7–24 months). The detailed protocol is included in the Supplemental Methods.

**Statistics**

Data were analyzed descriptively, and median [interquartile range (IQR)] or count (percentage) as well as the number of available patients (n) is presented. Differences between pre- and post-BAT treatment measurements were analyzed using the Wilcoxon signed-rank tests and test of marginal homogeneity. Resulting two-sided p values are presented and considered statistically significant if ≤0.05. CPET parameters were retrospectively collected only once before and after the implementation of BAT. All other parameters were collected retrospectively 6 and 12 months after activation of BAT. As the time spans for each outcome variable differed slightly, the time-points are simplified in the results as first (~6 months) and second (~12 months) follow-up for better readability, and the exact time spans are provided as mean value ± standard deviation in Supplemental Table 1. Analyses were performed in SPPS Statistics 25 (IBM Corp., Armonk, NY, USA).

Owing to the retrospective design, data were not available for all patients at all time-points. Median (IQR) values presented in the article refer only to paired data sets. Because of this form of data presentation, the baseline values for each follow-up differ. Median (IQR) values of all available data from all patients at a given time-point are presented in Supplemental Table 2.

**Results**

**Baseline characteristics**

A total of 17 patients with HFrEF were treated with BAT at our center. A total of 16 (94.1%) patients were in NYHA class III before activation of BAT and one (5.9%) in NYHA class IV. All patients were on stable guideline-directed medical and device therapy before establishing BAT. The details on baseline characteristics, medication, and device treatment are presented in Table 1.

**CPET**

Twelve of 17 (70.6%) patients underwent CPET examination before and after activation of BAT (see Table 2). Baseline CPET examination was 0.7 ± 0.6 months before, and follow-up was 8.9 ± 6.4 months after BAT activation.

Peak VO\textsubscript{2} was 0.9 (0.57–1.6) l/min at baseline and 1.2 (0.8–1.5) l/min after BAT (p = 0.071). Weight-adapted peak VO\textsubscript{2} increased significantly from 10.1 (8.2–12.9) ml/min/kg before BAT to 12.1 (10.4–14.6) ml/min/kg after BAT (p = 0.041). Body weight did not change with 92.5 (85.5–115.3) kg at baseline and 91.0 (82.8–111.8) kg at follow-up (p = 0.779). Maximal heart rate was stable with 105 (88–114.3) bpm at baseline and 114 (88.3–120.8) bpm at follow-up (p = 0.385). Peak oxygen pulse did not change with 10.2 (5.7–13.0) ml/heartbeat at baseline and 10.3 (7.8–15.8) ml/heartbeat at follow-up in the whole cohort (p = 0.084). When excluding two patients with a high maximal oxygen pulse (>16.5 ml/heartbeat) already at baseline, the remaining cohort showed a significant improvement of peak oxygen pulse from 9.7 (5.5–11.3) ml/heartbeat to 9.9 (7.1–12.1) ml/heartbeat (n = 10, p = 0.047; see Figure 1); mean values increased from 8.7 to 10.5 ml/heartbeat. Peak circulatory power increased numerically from 1268.8 (837.5–1638.7) mmHg × mlO\textsubscript{2} × min\textsuperscript{−1} × kg\textsuperscript{−1} to 1512 (1207.9–1952.1) mmHg × mlO\textsubscript{2} × min\textsuperscript{−1} × kg\textsuperscript{−1} (p = 0.214, n = 9). There was no significant difference in maximal workload and maximal blood pressure under treatment with BAT.

VE/VCO\textsubscript{2}-slope remained stable with 37.5 (28.9–52.9) before and 37.8 (35–44.5) after treatment.
with BAT ($p = 0.583$). PETCO$_2$ was stable with $33.6\ (28.6–36.3)\ mmHg$ before BAT and $32.2\ (30.3–35.9)\ mmHg$ after BAT ($p = 0.937$).

We performed another analysis at a submaximal workload of 15 watts as data were available for each patient at this workload. Weight-adapted VO$_2$ showed an increase of borderline significance at submaximal workload from $5.5\ (4.5–6.2)\ ml/min/kg$ at baseline to $6.4\ (5.5–7.1)\ ml/min/kg$ at follow-up ($p = 0.050$; see Supplemental Table 3). No significant changes were found for the other parameters at submaximal workload.

### Table 1. Baseline characteristics.

| Variable                     | Baseline ($n=17$)          |
|------------------------------|---------------------------|
| Age (years)                  | $55.1\ ±\ 12.8$          |
| Sex (% female)               | $3\ (17.6)$               |
| BMI (kg/m$^2$)               | $30.2\ ±\ 5.2$           |
| Smokers (%)                  | $8\ (47.1)$               |
| HbA1c (%)                    | $6.6\ (5.7–7.6)\ (n=16)$  |
| SBP (mmHg)                   | $114\ (99.5–124)$         |
| DBP (mmHg)                   | $71\ (64–80.5)$           |
| NYHA class III (%)           | $16\ (94.1)$              |
| LVEF (%)                     | $30\ (21–30)\ (n=15)$     |
| ACE inhibitors/ARBs (%)$^a$  | $17\ (100)$               |
| β-blockers (%)               | $16\ (94.1)$              |
| MRA (%)                      | $12\ (70.6)$              |
| Ivabradine (%)               | $3\ (17.6)$               |
| Diuretics (%)                | $17\ (100)$               |
| Digitalis glycosides (%)     | $4\ (23.5)$               |
| ICD (%)                      | $10\ (58.8)$              |
| CRT-D (%)                    | $4\ (23.5)$               |

ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CRT-D, cardiac resynchronization therapy–defibrillator; DBP, diastolic blood pressure; ICD, implantable cardioverter–defibrillator; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid-receptor antagonist; NYHA, New York Heart Association; SBP, systolic blood pressure.

Values are presented as median (IQR) or count (%). Age and BMI are presented as mean value ± standard deviation.

$^a$As sacubitril/valsartan was not yet available; none of the patients were treated with this drug.

**Effect of BAT on symptoms, 6MHW, LVEF, and laboratory values**

At first follow-up, seven patients had improved from NYHA class III to II and one patient from NYHA class IV to III. Thus, at first follow-up, there was a significant improvement with seven patients being in NYHA class II (43.8%) and nine in class III (56.3%; $n=16$, $p = 0.005$). At second follow-up, four patients were in class II (30.8%) and nine patients in class III (69.2%; $n=13$, $p = 0.052$ versus baseline).

Further efficacy endpoints and laboratory values are presented in detail in Table 3 (6 months follow-up) and Table 4 (12 months follow-up). There was a significant improvement of 6MHW from $355\ (286.8–412.5)\ m$ at baseline to $395\ (350.3–452.5)\ m$ at second follow-up ($n=6$, $p = 0.046$). No effect on quality of life assessed by MLHFQ score was noticed. LVEF was increased from $29.5\ (19.5–30)\ %$ at baseline to $30.5\ (27.8–35.5)\ %$ at second follow-up ($n=8$, $p = 0.025$).

There was no significant change in NTproBNP. eGFR decreased significantly from $84.5\ (50.3–87.8)\ ml/min$ at baseline to $64.5\ (40.5–93.3)\ ml/min$ at second follow-up ($n=12$, $p = 0.031$), with a corresponding increase in serum creatinine. Normetanephrine and metanephrine levels were stable.

**Safety**

Systolic and diastolic blood pressure as well as heart rate remained stable (see Tables 3 and 4). In seven of 17 patients, follow-up was limited by clinical events. One BAT device had to be explanted because of a local infection after 9 months. Three patients died 3, 15, and 16 months after BAT had been established; there was no association to BAT. One patient demanded deactivation of BAT 26 months after implantation, because of pain in the left arm, which was probably not related to BAT, as far as our experience goes. Two patients underwent heart transplantation 6 months and 3 years after BAT.

CPET proved to be safe. All patients tolerated the procedure well, and no adverse events occurred.

**Discussion**

In this single-center, open-label study on HFrEF patients treated by BAT, we present first data on
cardiopulmonary function assessed by CPET, which point toward an improved exercise capacity and circulatory efficiency.

The most important novel finding of this study was that weight-adapted peak VO₂ was improved significantly in HFrEF patients under BAT, reflecting the enhanced exercise capacity and heart failure symptoms shown in the present and previous trials. Weight-adapted peak VO₂ is a prognostic indicator in HFrEF. Keteyian et al. found that a peak VO₂ of 9.2 ml/min/kg was associated with 10% 1 year all-cause mortality in patients with HFrEF, whereas a peak VO₂ of 16.9 ml/min/kg carried only a 3% risk. In this study, BAT improved peak VO₂ from ~10 to ~12 ml/min/kg in severely compromised patients. According to the data of Keteyian et al., this may potentially translate into a reduction in 1-year all-cause mortality from ~13% to ~9% for men and from ~7% to ~3% for women.

Patients with HFrEF have an autonomic disbalance with high sympathetic tone which poses a high risk of adverse events and makes the autonomic system a promising therapeutic target in HFrEF. Gronda et al. have demonstrated by recordings of MSNA that sympathetic nerve traffic decreases under BAT. While MSNA decreases in healthy people during exercise, it increases in patients with HFrEF. Exercise training was able to reduce MSNA at rest and under mild exercise and to improve peak VO₂. There may be a causal link between MSNA reduction and improved exercise performance and peak VO₂, as reductions in muscle blood flow due to high sympathetic tone may constrain exercise performance. This may explain the improved peak VO₂ observed here under BAT.

Resetting of peripheral baroreceptors as well as a central resetting of baroreceptor input has been described. Electrical stimulation of baroreceptors would not be expected to have a sustained benefit if resetting was complete. Thus, the sustained

| Variable                                                                 | Baseline          | Follow-up         | p value | n |
|--------------------------------------------------------------------------|-------------------|-------------------|---------|---|
| **Baseline**                                                             | **Follow-up**     | **p value**       |         |   |
| Peak VO₂ (l/min)                                                         | 0.91 (0.57–1.6)   | 1.2 (0.8–1.5)     | 0.071   | 12|
| Weight-adapted peak VO₂ (ml/min/kg)                                     | 10.1 (8.2–12.9)   | 12.1 (10.4–14.6)  | 0.041   | 12|
| Maximal heart rate (bpm)                                                | 105 (88–114.3)    | 114 (88.3–120.8)  | 0.385   | 12|
| Maximal oxygen pulse (ml/heartbeat)                                     | 10.2 (5.7–13.0)   | 10.3 (7.8–15.8)   | 0.084   | 12|
| Maximal oxygen pulse in patients with <16.5 ml/heartbeat at baseline (ml/heartbeat) | 9.7 (5.5–11.3)   | 9.9 (7.1–12.1)   | 0.047   | 10|
| VE/VCO₂-slope                                                           | 37.5 (28.9–52.9)  | 37.8 (35–44.5)    | 0.583   | 12|
| PETCO₂ (mmHg)                                                           | 33.6 (28.6–36.3)  | 32.2 (30.3–35.9)  | 0.937   | 12|
| Maximal workload (watts)                                                | 75.0 (41.3–111.3) | 75.0 (65.0–107.5) | 0.449   | 12|
| Maximal systolic BP (mmHg)                                              | 122.0 (106.0–131.5)| 117.0 (103.5–144.5)| 0.767 | 9 |
| Maximal diastolic BP (mmHg)                                             | 81.0 (73.5–84.0)  | 79.0 (68.0–87.0)  | 0.812   | 9 |
| Peak circulatory power (mmHg × mlO₂ × min⁻¹ × kg⁻¹)                     | 1268.8 (837.5–1638.7) | 1512.0 (1207.9–1952.1) | 0.214 | 9 |

BAT, baroreflex activation therapy; BP, blood pressure; bpm, beats per minute; peak VO₂, maximal oxygen consumption; PETCO₂, partial pressure of end-tidal carbon dioxide; VE/VCO₂, minute ventilation/carbon dioxide production.
reduction in MSNA reported by Gronda et al. up to 6 months after initiation of BAT and the sustained benefit on peak VO$_2$ and other exercise parameters reported by the present and previous studies$^{2,6,7,18}$ argue against a complete resetting at the level of the baroreceptors and the central nervous system. On the other side, resetting may at least partly explain the variable response of patients to BAT.

Oxygen pulse rose numerically in the whole cohort, but this did not reach statistical significance. Two patients had a high oxygen pulse (>16.5 ml/
heartbeat) already at baseline, which may have made a further increase difficult to achieve. In the 10 patients with low oxygen pulse at baseline, a significant improvement was observed. As heart rate was not increased but even numerically decreased in this study, the improvement of oxygen uptake and oxygen pulse indicates an improvement in circulatory efficiency under BAT, that is, a beneficial effect on stroke volume and peripheral oxygen extraction, based on the Fick Equation (\(\text{VO}_{2} = \text{heart rate} \times \text{stroke volume} \times \text{arteriovenous oxygen content difference}\)).

BAT had a neutral effect on other CPET parameters. VE/VCO\(_2\)-slope stayed stable on a high level, so ventilatory efficiency was not influenced by BAT. High VE/VCO\(_2\)-slope values indicate a higher risk of hospitalization and death. PETCO\(_2\), which was stable under BAT on a low level <33 mmHg, is also associated with higher mortality. These observations emphasize the severity of heart failure in our cohort.

NTproBNP dropped numerically, but this did not reach statistical significance, which may be explained by the low patient number. In the Baroreflex activation therapy for heart failure (BEAT-HF) trial, a significant drop of NTproBNP was only found in patients with initial NTproBNP <1600 pg/ml. In this population, which was defined as intended use population during the course of the study, a significant 21% decrease of NTproBNP was observed after 6 months. Taking into account only patients with a baseline NTproBNP of <1600 pg/ml, BAT resulted in a 41% decrease of NTproBNP after 6 months in this study, but this did also not reach statistical significance [602 (210–992) pg/ml at baseline to 354 (226–897) pg/ml at follow-up; \(n=7, p=0.236\)]. A post hoc analysis of the BAT-HF trial investigated the response to BAT depending on sex. While baseline values of NTproBNP did not differ in women and men, only women showed a significant decrease in NTproBNP under BAT. Only 17.6% of our

---

**Table 3.** Efficacy endpoints and laboratory values at 6-month follow-up after BAT activation, only paired values.

| Variable               | Baseline Median (IQR) | 6-month follow-up Median (IQR) | n | p value |
|------------------------|-----------------------|---------------------------------|---|---------|
| 6MHW (m)               | 350 (157–400)         | 330 (250–400)                   | 7 | 0.345   |
| MLHFQ                  | 50.0 (43–62)          | 44 (34–68)                      | 7 | 0.866   |
| LVEF [%]               | 30 (19.5–31.5)        | 33 (25.5–36.8)                  | 8 | 0.090   |
| NTproBNP [pg/ml]       | 1769.5 (605–4565.5)   | 929.5 (393.5–2226.8)            | 16| 0.056   |
| eGFR [ml/min]          | 66 (54–87)            | 57 (49–73)                      | 15| 0.069   |
| Serum creatinine [mg/dl]| 1.1 (1.0–1.4)        | 1.2 (0.9–1.5)                   | 17| 0.325   |
| Urea [mg/dl]           | 41 (27–60)            | 45 (30–84)                      | 17| 0.193   |
| Normetanephrines [pg/ml]| 181.5 (107.2–211.3) | 152.5 (89.5–212.5)              | 10| 0.878   |
| Metanephrines [pg/ml]  | 44.8 (27.6–54.4)      | 40.1 (31.6–49.2)                | 10| 0.646   |
| SBP [mmHg]             | 110.5 (98.8–126)      | 108.5 (101.3–118.3)             | 16| 0.179   |
| DBP [mmHg]             | 71 (63–79.5)          | 74.5 (65.3–83.3)                | 16| 0.609   |
| Pulse pressure [mmHg]  | 38 (31.5–50.8)        | 32 (29.3–38.5)                  | 16| 0.006   |
| Heart rate [bpm]       | 70.5 (62.5–86)        | 72.5 (64–86.3)                  | 16| 0.733   |

Bold \(p\) values indicate statistical significance.

6MHW, 6-min hall walk; bpm, beats per minute; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; MLHFQ, Minnesota Living with Heart Failure Questionnaire; NTproBNP, N-terminal pro-brain natriuretic peptide; SBP, systolic blood pressure.
Table 4. Efficacy endpoints and laboratory values at 12-month follow-up after BAT activation, only paired values.

| Variable               | Baseline Median (IQR) | 12-month follow-up Median (IQR) | n   | p value |
|------------------------|-----------------------|---------------------------------|-----|---------|
| 6MHW [m]               | 355 (286.8–412.5)     | 395 (350.3–452.5)               | 6   | 0.046   |
| MLHFQ                  | 52 (39.5–63.3)        | 40.5 (21.5–64)                  | 6   | 0.500   |
| LVEF (%)               | 29.5 (19.5–30)        | 30.5 (27.8–35.5)                | 8   | 0.025   |
| NTproBNP [pg/ml]       | 2102.5 (897.5–5709.8) | 1227.5 (676–3151)               | 10  | 0.241   |
| eGFR [ml/min]          | 84.5 (50.3–87.8)      | 64.5 (40.5–93.3)                | 12  | 0.031   |
| Serum creatinine [mg/dl]| 1.14 (1.0–1.4)       | 1.2 (0.9–1.7)                   | 14  | 0.048   |
| Urea [mg/dl]           | 40.5 (27.5–50.3)      | 46.5 (28.8–66)                  | 14  | 0.100   |
| Normetanephrines [pg/ml]| 160 (66.9–201)       | 139 (78.5–239.3)                | 6   | 0.917   |
| Metanephrines [pg/ml]  | 44.8 (29.7–67.3)      | 41.9 (30.9–61)                  | 8   | 0.575   |
| SBP [mmHg]             | 106 (98–120)          | 109 (93–127)                    | 11  | 0.929   |
| DBP [mmHg]             | 69 (62–80)            | 63 (61–92)                      | 11  | 0.373   |
| Pulse pressure [mmHg]  | 39 (36–44)            | 35 (29–39)                      | 11  | 0.212   |
| Heart rate [bpm]       | 69 (62.5–79.8)        | 69 (61.5–92.5)                  | 12  | 0.783   |

Bold p values indicate statistical significance. 6MHW, 6-min hall walk; bpm, beats per minute; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; MLHFQ, Minnesota Living with Heart Failure Questionnaire; NTproBNP, N-terminal pro-brain natriuretic peptide; SBP, systolic blood pressure.

As norepinephrine and epinephrine correlate with sympathetic activity, the concentration of their metabolites normetanephrines and metanephrines is considered as markers of sympathetic activity. These markers were stable after BAT, which is in contrast to the decrease of norepinephrine observed in dogs with pacing-induced heart failure treated with BAT and the reduction in MSNA reported by Gronda et al. It is probable that the high standard deviation of lab values and low patient number of the present trial impaired the validity of this analysis.

Limitations
Because of the low number of patients enrolled and the retrospective evaluation of the database, the findings of this trial must be interpreted very carefully and must be regarded as hypothesis generating. This major limitation of this study is related to the novelty of the treatment and the low number of patients treated with BAT worldwide.

Another important limitation is that patients and investigators were unblinded, and there was no control group, which could have led to an overestimation of the observed effects. On the other side, our findings on CPET are plausible and in line with previous observations from other HFrEF trials. A total of 23.5% of patients enrolled were treated with cardiac resynchronization therapy (CRT) before BAT. Studies have shown that CRT has a positive effect on the autonomic imbalance, which may lead to a better response to BAT in patients without CRT. This may have diminished effects of BAT observed in this study.

Patients were not treated with an angiotensin receptor–neprylisin inhibitor (ARNI) or sodium-glucose co-transporter-2 (SGLT2) inhibitors,
which were not available at the time of data collection. It is speculative and should be the scope of future trials on BAT (and other established device therapies), whether device-related beneficial effects are preserved in patients with current state-of-the-art medical therapy.

**Conclusion**

Weight-adapted peak oxygen uptake improved after BAT, pointing to an enhanced exercise capacity. Ventilatory efficiency and heart rate did not change, while oxygen pulse increased in patients with low oxygen pulse at baseline, indicating an improvement in circulatory efficiency, that is, a beneficial effect on stroke volume and peripheral oxygen extraction.

**Declarations**

**Ethics approval and consent to participate**

The protocols of the multicenter prospective registry and randomized trial conformed to the Declaration of Helsinki and were approved by the local ethics committee and regulatory authorities. Additional local investigations were also approved by the local ethics committee (no. 15-344). Patients provided written informed consent for all investigations before enrollment.

**Consent for publication**

All authors gave their consent for publication.

**Author contributions**

**Pia I. Nottebohm:** Data curation; Formal analysis; Investigation; Methodology; Visualization; Writing – original draft.

**Daniel Dumitrescu:** Conceptualization; Supervision; Validation; Writing – review & editing.

**Stefanie Hamacher:** Formal analysis; Methodology.

**Christopher Hohmann:** Data curation.

**Navid Madershahian:** Conceptualization; Resources; Supervision.

**Stephan Baldus:** Conceptualization; Resources; Supervision.

**Hannes Reuter:** Conceptualization; Resources; Supervision.

**Marcel Halbach:** Conceptualization; Investigation; Project administration; Supervision; Validation; Writing – review & editing.

**Acknowledgements**

The authors acknowledge the assistance of Tatjana Schewior as well as the support provided by Michael Steinkamp and Seth Wilks from CVRx Inc.

**Funding**

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: All patients participated in a multicenter postmarket BAT registry or a randomized trial funded by CVRx Inc., but CPET data were not included in these studies and all other parameters were not derived from study databases but from our local clinical database.

**Competing interests**

The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: M.H., N.M., and H.R. received speaker or consultant honoraria and research grants from CVRx Inc. P.I.N., D.D., S.H., C.H., and S.B. have no conflicts of interest regarding the content of this article.

**Availability of data and materials**

Anonymized raw data may be shared with other researchers on request.

**ORCID iDs**

Pia I. Nottebohm https://orcid.org/0000-0002-3158-3099

Marcel Halbach https://orcid.org/0000-0002-6361-5825

**Supplemental material**

Supplemental material for this article is available online.

**References**

1. Brunner-La Rocca HP, Esler MD, Jennings GL, *et al.* Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. *Eur Heart J* 2001; 22: 1136–1143.
2. Abraham WT, Zile MR, Weaver FA, et al. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction. *JACC Heart Fail* 2015; 3: 487–496.

3. Halbach M, Fritz T, Madershahian N, et al. Baroreflex activation therapy in heart failure with reduced ejection fraction: available data and future perspective. *Curr Heart Fail Rep* 2016; 13: 71–76.

4. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. *Circulation* 1996; 94: 2807–2816.

5. Ponikowski P, Voors AA, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur J Heart Fail* 2016; 18: 891–975.

6. Gronda E, Seravalle G, Brambilla G, et al. Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study. *Eur J Heart Fail* 2014; 16: 977–983.

7. Zile MR, Lindenfeld J, Weaver FA, et al. Baroreflex activation therapy in patients with heart failure with reduced ejection fraction. *J Am Coll Cardiol* 2020; 76: 1–13.

8. Weaver FA, Abraham WT, Little WC, et al. Surgical experience and long-term results of baroreflex activation therapy for heart failure with reduced ejection fraction. *Semin Thorac Cardiovasc Surg* 2016; 28: 320–328.

9. Herdy AH, Ritt LE, Stein R, et al. Cardiopulmonary exercise test: background, applicability and interpretation. *Arq Bras Cardiol* 2016; 107: 467–481.

10. Cahalin LP, Chase P, Arena R, et al. A meta-analysis of the prognostic significance of cardiopulmonary exercise testing in patients with heart failure. *Heart Fail Rev* 2013; 18: 79–94.

11. Ketyeyan SJ, Patel M, Kraus WE, et al. Variables measured during cardiopulmonary exercise testing as predictors of mortality in chronic systolic heart failure. *J Am Coll Cardiol* 2016; 67: 780–789.

12. van Bilsen M, Patel HC, Bauersachs J, et al. The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2017; 19: 1361–1378.

13. Mortara A, La Rovere MT, Pinna GD, et al. Arterial baroreflex modulation of heart rate in chronic heart failure. *Circulation* 1997; 96: 3450–3458.

14. Sabbah HN, Gupta RC, Imai M, et al. Chronic electrical stimulation of the carotid sinus baroreflex improves left ventricular function and promotes reversal of ventricular remodeling in dogs with advanced heart failure. *Circ Heart Fail* 2011; 4: 65–70.

15. Notarius CF, Millar PJ, Keir DA, et al. Training heart failure patients with reduced ejection fraction attenuates muscle sympathetic nerve activation during mild dynamic exercise. *Am J Physiol – Regul Integr Comp Physiol* 2019; 317: R503–R512.

16. Keir DA, Notarius CF, Badrov MB, et al. Heart failure-specific inverse relationship between the muscle sympathetic response to dynamic leg exercise and VO2 peak. *Appl Physiol Nutr Metab* 2021; 46: 1119–1125.

17. Chapleau MW, Hajduczok G and Abboud FM. Peripheral and central mechanisms of baroreflex resetting. *Clin Exp Pharmacol Physiol Suppl* 1989; 15: 31–43.

18. Gronda E, Francis D, Zannad F, et al. Baroreflex activation therapy: a new approach to the management of advanced heart failure with reduced ejection fraction. *J Cardiovasc Med (Hagerstown)* 2017; 18: 641–649.

19. Del Buono MG, Arena R, Borlaug BA, et al. Exercise intolerance in patients with heart failure: JACC state-of-the-art review. *J Am Coll Cardiol* 2019; 73: 2209–2225.

20. Chua TP, Ponikowski P, Harrington D, et al. Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure. *J Am Coll Cardiol* 1997; 29: 1585–1590.

21. Arena R, Peberdy MA, Myers J, et al. Prognostic value of resting end-tidal carbon dioxide in patients with heart failure. *Int J Cardiol* 2006; 109: 351–358.

22. Lindenfeld J, Gupta R, Grazier L, et al. Response by sex in patient-centered outcomes with baroreflex activation therapy in systolic heart failure. *JACC Heart Fail* 2021; 9: 430–438.

23. Floras JS and Ponikowski P. The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction. *Eur Heart J* 2015; 36: 1974–1982.

24. Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident...
cardiovascular events in patients with end-stage renal disease. *Circulation* 2002; 105: 1354–1359.

25. Zucker IH, Hackley JF, Cornish KG, et al. Chronic baroreceptor activation enhances survival in dogs with pacing-induced heart failure. *Hypertension* 2007; 50: 904–910.

26. Swank AM, Horton J, Fleg JL, et al. Modest increase in peak VO₂ is related to better clinical outcomes in chronic heart failure patients. *Circ Heart Fail* 2012; 5: 579–585.

27. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. *N Engl J Med* 2002; 346: 1845–1853.

28. Vitale G, Romano G, Di Franco A, et al. Early effects of sacubitril/valsartan on exercise tolerance in patients with heart failure with reduced ejection fraction. *J Clin Med* 2019; 8: 262.

29. Dunselman PH, van der Mark TW, Kuntze CE, et al. Different results in cardiopulmonary exercise tests after long-term treatment with felodipine and enalapril in patients with congestive heart failure due to ischaemic heart disease. *Eur Heart J* 1990; 11: 200–206.

30. Zile MR, Abraham WT, Weaver FA, et al. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy. *Eur J Heart Fail* 2015; 17: 1066–1074.